Diag-Nose
We use AI and protein signatures to help the one billion chronic respiratory patients worldwide find the right treatment, faster, so they can breathe better and live longer.
Related Content
Diag-Nose.io leverages biological (“omics”) data and AI to revolutionize diagnostics and drug discovery for chronic respiratory disorders including chronic sinusitis and asthma; i.e. chronic conditions which affect one billion patients worldwide.
Diag-Nose.io’s flagship product (The RhinoMAP) is an AI-enabled laboratory testing platform that aims to provide specialists with improved patient access, triage, treatment selection and monitoring, with a particular focus on high-cost anti-Th2 biologics.
Diag-Nose.io is a graduate of the Stanford ENT 2019 Innovation program, MedTech Actuator program, ANDHealth ACTIVATE program and the Creative Destruction Lab (CDL) 2022 program – Computational Health Stream in Seattle, becoming their first Australian MedTech alumni company. CDL is recognised as the leading accelerator program in the world for deeptech/science-based companies.